Figure 1.

Incremental cost-effectiveness of implementing JNC 8 hypertension treatment guidelines in previously untreated non-Hispanic black (NHB) and non-Hispanic white (NHW) adults with hypertension aged 35–74 years, by age, sex, hypertension stage, and status of diabetes or chronic kidney disease (CKD). Within age and sex row, each group is compared with the higher risk group to its left; stage 2 hypertension is compared with patients living with cardiovascular disease (CVD) and hypertension. Average annual results from a years 2014–2024 simulation, the CVD policy model. Abbreviation: ICER = incremental cost-effectiveness ratio.